Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNU6-179P** is a human **pseudogene** derived from the U6 small nuclear RNA (snRNA) locus. U6 snRNA itself is a highly conserved, essential component of the spliceosomal machinery and participates in the excision of introns from pre-mRNA as part of the spliceosome[3][1]. However, RNU6-179P is a retrotransposed, non-functional copy of the U6 snRNA gene. Pseudogenes like RNU6-179P are formed by processed retrotransposition mechanisms, often mediated by LINE-1 (L1) elements, and are not transcribed into functional RNAs nor do they participate in canonical snRNP or spliceosome activity[7]. Their presence in the genome mainly reflects historical events of genome evolution and retrotransposition and may serve as markers of L1 activity rather than as functional biological entities[7].\n\nIf you are seeking a therapeutically relevant target, you likely want the **U6 small nuclear RNA** itself, not one of its pseudogenes. The U6 snRNA is crucial for **spliceosome function** and RNA splicing, but no drugs are known to directly target this RNA and it is not conventionally classified as a drug target, enzyme, receptor, or transporter[3][1].
Not applicable
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 179, pseudogene (RNU6-179P).